Key statistics
On Monday, Minerva Neurosciences Inc (NERV:NAQ) closed at 6.90, -44.62% below its 52-week high of 12.46, set on Oct 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.42 |
|---|---|
| High | 6.92 |
| Low | 6.23 |
| Bid | 6.50 |
| Offer | 6.85 |
| Previous close | 6.60 |
| Average volume | 109.72k |
|---|---|
| Shares outstanding | 43.27m |
| Free float | 41.72m |
| P/E (TTM) | -- |
| Market cap | 285.61m USD |
| EPS (TTM) | -1.85 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
- Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
- Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
- Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
- Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
More ▼
